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Studies evaluating circulating endothelial cells by ﬂow cytometry are faced by a lack of con-
sensus about the best combination of monoclonal antibodies to be used. The rarity of these
cells in peripheral blood, which represent 0.01% of mononuclear cells, drastically increases
this  challenge.
Objective: The aim of this study is to suggest some combinations of markers that would
safely and properly identify these cells.
Methods: Flow cytometry analysis of circulating endothelial cells was performed applying
three different panels composed of different combinations of the CD144, CD146, CD31,
CD133, CD45 and anti-Vascular endothelial growth factor receptor-2 antibodies.
Results: In spite of the rarity of the events, they were detectable and presented similar inter-
person numbers of circulating endothelial cells.
Conclusion: The combination of markers successfully identiﬁed the circulating endothelial
cells in healthy individuals, with the use of three different panels conﬁrming the obtained
data as reliable.
© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.Introduction
Endothelial cells, located in the intima layer of blood vessels,
evolve during the vasculogenesis process in the embryonic
period. The circulating form of these cells was ﬁrst described
in 1970 and challenged the traditional concept that endothe-
lial regeneration and angiogenesis occurred exclusively via
the proliferation of the pre-existing resident vessel wall of
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reserved.endothelial cells.1,2 The ﬁrst studies, performed by two groups,
reported that human CD34+ cells, isolated from circulating
peripheral blood, umbilical cord blood and bone marrow, could
differentiate into endothelial cells in vitro and in vivo in mouse
models, thereby contributing to neoendothelialization and
neovascularization in the adult organism.3,4 Campinas, Universidade Estadual de Campinas (UNICAMP), Rua
nto).
Nowadays these circulating endothelial cells (CEC) are well
described as originating from the vascular wall or recruited
from the bone marrow (progenitor endothelial cells).3
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Table 1 – Monoclonal antibodies employed in circulating
endothelial cells analyses.
Antibody Clone Fluorochrome Manufacturer
CD31(+) MBC78.2;
PECAM1.2
FITC Invitrogen
CD45(−) 2D1 PerCP Becton
Dickinson
CD133(−) AC133 APC Miltenyi
Biotec
CD144(+) TEA1/31 PE Beckman
Coulter
CD146(+) P1H12 PE Becton
Dickinson
VEGFR2(+) 89106 PE R&D
IgGs – FITC
PE
Dako
detector which was lowered in order to include lymphocytes.
Platelets, debris and leucocytes were excluded according to
their FCS × SSC and SSC × CD45 positions. CEC were analyzed
Table 2 – Monoclonal antibodies applied in the
identiﬁcation and quantiﬁcation of mature circulating
endothelial cells.
Panel Monoclonal antibodies
1 CD31 FITC(+), CD144 PE(+), CD45 PerCP(−)
and CD133 APC(−)
2 CD31 FITC(+), CD146 PE(+), CD45 PerCP(−)rev bras hematol hemo
revious studies described proliferating clusters of endothe-
ial cells in vessels with no sign of vascular denudation or
njury, which supports the theory of endogenous endothelial
eplacement.5–7 In different ischemic models, the rate of incor-
oration of bone marrow-derived cells ranges from 0% to 57%
ut achieves 80% in vascular grafts.8–10
Increased numbers of these cells have been identiﬁed
n response to ischemia and vascular trauma11,12 in acute
yocardial infarction,13 sickle cell anemia,14 vasculitis,15
ulmonary hypertension16 and these cells have also been
ttributed angiogenic potential.17 Some authors have also
ostulated that CEC may act as a novel marker to distinguish
etween quiescent and active disease states, such as in sickle
ell anemia, thalassemia, Kawasaki’s disease, and various
ancers.14,18–20 CEC seem to play an active role in hemosta-
is, blood coagulation and ﬁbrinolysis, platelet and leukocyte
nteractions with the vessel wall, lipoprotein metabolism, his-
ocompatibility antigen presentation, muscle tone regulation
nd arterial pressure.21
Although the gold-standard method to evaluate CEC is ﬂow
ytometry, the determination of CECs has proved to be difﬁ-
ult due the lack of a speciﬁc monoclonal antibody against
he cells22–24 and the absence of a consensus regarding the
est combination of markers. Considering that, no consensus
as been reached until this moment as to which is the best
anel to accurately identify endothelial cells and the under-
tanding of the importance of accurately analyzing these cells,
he aim of this paper is to propose a combination of mark-
rs that together may perform this analysis. The deﬁnition of
n appropriate panel to study these cells is crucial to make it
ossible to compare the results of different research groups.
ethods
n this study, CEC were analyzed by ﬂow cytometry apply-
ng three different panels composed of the antibodies CD144,
D146, CD31, CD133, CD45 and anti-Vascular endothelial
rowth factor receptor-2 (VEGFR2), remembering that these
ells can present more  than one phenotype.
This study was approved by the local Research Ethics Com-
ittee and was in accordance with the Declaration of Helsinki.
fter signing written informed consent forms, 8 mL of periph-
ral blood were collected from the antecubital vein of 20 blood
onors (10 male, 10 female; mean age: 34.4 ± 2.2 years) at
he Hemocentro in Campinas/UNICAMP. Participants were not
aking any medications. The collection was performed using
wo vacuum tubes (Greiner Bio-One, Kremsmunster, Austria)
ontaining Ethylenediaminetetraacetic acid (EDTA), with the
rst tube being used exclusively for blood counts due to pos-
ible contamination with traces of collagen, thrombin25 and
ndothelial cells during venipuncture.26 The second tube was
sed for ﬂow cytometry analysis. Preparation of the samples
as carried out immediately after collection, and were subse-
uently stored at 4 ◦C until ﬂow cytometry.
Absolute CEC number was derived from the white
lood cell count, and deﬁned as positive for CD31, CD144,
D146, VEGFR2 and negative for CD45 and CD133.3,23
he mouse anti-human conjugated antibodies used were
uorescein isothiocyanate (FITC)-labeled anti-CD31 (clonePerCP
APC
MBC78.2; PECAM1.2, Invitrogen), anti-CD34 (clone 8G12; Bec-
ton Dickinson, Bioscences), phycoerthrin (PE)-labeled CD144
(clone TEA1/31, Beckman Coulter), anti-CD146 (clone P1H12,
BD Bioscences), anti-VEGFR2 (clone 89106, R&D), peri-
dinim chlorophyll (PerCP)-labeled anti-CD45 (clone 2D1, BD
Bioscences), and allophycocianin (APC)-labeled anti-CD133
(clone AC133, Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many)  (Table 1). Three different panels were created in three
tubes in an attempt to characterize CEC with different pheno-
types as shown in Table 2.
A quantity of 100 L of blood (with a leukocyte concen-
tration between 5 and 10 × 103/L) was incubated with the
ﬂuorochrome-labeled monoclonal anti-human antibodies for
20 min  at 4 ◦C in the dark for the staining procedure. The blood
count was performed using a hematological analyzer (Cell
Dyn®; Abbott Laboratories, IL, USA). Red blood cells were lysed
by adding 2 mL  of FACS lysing solution (diluted at 1:10; Becton
Dickinson) for 10 min  at 4 ◦C. The remaining leucocytes were
washed with 2 mL  2% phosphate buffered saline/bovine serum
albumin buffer (PBS/BSA) at pH = 7.4, centrifuged at 600 × g for
5 min  and resuspended in 500 L of wash buffer. The acqui-
sition of 500,000 cells or the total volume of the tube was
performed using a FACScalibur® ﬂow cytometer (Becton Dick-
inson, San Jose, CA, USA) and analyzed by Cell-Quest® and
Paint-a-Gate® computer programs (BD, Bioscences).
The threshold was deﬁned by a forward scatter (FSC)and CD133 APC(−)
3 CD31 FITC(+), VEGFR2 PE(+), CD45 PerCP(−)
and CD133 APC(−)
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Figure 1 – Analysis strategy for the identiﬁcation of mature circulating endothelial cells (CEC) by ﬂow cytometry. The
 the negative population for CD45 was selected and analyzed for
CD133 anti-VEGFR2).
according to CD144 × CD31 × CD133, CD146 × CD31 × CD133
and anti-VEGFR2 × CD31 × CD133 characteristics. The strategy
applied in these CEC analyzes is shown in Figure 1.
Statistical  analysis
Data are presented as mean ± standard error of the mean
(SEM). The Mann–Whitney test was used to compare con-
tinuous variables. Analyses were performed using the R
Development Core Team 2010 Software (Vienna, Austria) and
p-values ≤0.05 were considered statistically signiﬁcant.Results
As predicted, these events were very rare, although detectable
by ﬂow cytometry using the aforementioned panels,positivity of endothelial markers (CD144, CD146, CD31 and
which gave similar inter-person numbers of CEC (Panel
1: 0.76 ± 0.16 cells/L; Panel 2: 0.75 ± 0.15 cells/L; Panel 3:
0.78 ± 0.16 cells/L). There was no signiﬁcant difference
regarding their quantiﬁcation (p-value = 0.9; Mann–Whitney
test), indicating that these markers presented similar patterns
of CEC expression in healthy individuals (Figure 2). However,
different clinical conditions modify this behavior.
Discussion
In this study, CEC numbers were evaluated in healthy indi-
viduals. As previously described in the literature, these events
17,27however rare, were detectable by ﬂow cytometry analysis.
The analysis of these cells has proved to be compli-
cated as there is no speciﬁc monoclonal antibody for their
identiﬁcation,23,24,28 and until now there is no consensus as to
rev bras hematol hemoter. 2
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Figure 2 – Quantiﬁcation by ﬂow cytometry of circulating
endothelial cells (CEC) with different endothelial markers
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he best combination of surface markers for this task. Thus,
n many  studies there is no certainty as to whether CECs
ave been correctly identiﬁed. However, CECs can be identiﬁed
s the cells expressing endothelial markers (CD146, CD144,
WF,  VEGFR2) in the absence of hematopoietic (CD45, CD14)
nd progenitor markers (CD34, CD133).15,17,29,30 Several proto-
ols have proposed the use of whole blood or a mononuclear
oncentrate obtained after enrichment with ﬁcoll paque to
dentify these cells by ﬂow cytometry. Sorting or magnetic
eads can also be used; however, this method presents the
ame limitations as ﬂow cytometry. Furthermore, the use of
agnetic beads rarely provides the precise purity of the elu-
riated cells as the method is generally performed with one
arker, such as CD146. Therefore, a second method, such as
uorescence microscopy, is usually required to conﬁrm and
uantify the CECs.17 Immunohistochemistry is not a good
ption for the same reasons aggravated by the extreme rarity
f these cells in peripheral blood, about 0.01% of mononuclear
lood cells,17,27 and a lack of staining could be erroneously
nterpreted as a false negative result. Therefore, none of these
ossibilities have emerged as the best choice, and an effective
omparison of results between laboratories is difﬁcult.31
Furthermore, several technical issues must be taken into
ccount in order to truly analyze rare cells such as CECs.
he ﬁrst step in the technique involves extensive cleaning
nd washing procedures to remove residual cells and parti-
les. Fluorochrome-matched isotype controls, currently not
avored for common assays, are fairly crucial in rare event
nalysis, where they provide a good estimate of nonspeciﬁc
inding of antibodies to cells. Khan et al. 17 mentioned that,
ven with freshly drawn peripheral blood, nonspeciﬁc binding
f isotype controls may be detected in 0.1–0.5% of analyzed
ells. In most clinical assays, these nonspeciﬁc-bindings do
ot signiﬁcantly affect data, but in the evaluation of rare
ells they do. In CEC analysis, these bindings can represent
 background higher than the speciﬁc cell events. Another
oint is the large number of cells (over 500,000) that must
e counted to obtain statistically meaningful numbers of rare
ells. In the current analyses, the ﬁrst step was the exclusion
f CD45(+) cells by the SSC × CD45 gate; however, as in some 0 1 5;3 7(2):98–102 101
individuals the limit between positive and negative popula-
tions is not very clear, the SSC × FSC gate was also utilized to
exclude discrepant events. Furthermore, the antigen expres-
sion may be variable and may involve other cell lines with
overlapping expression of antigens. For instance, CD146 rec-
ognize MUC18/S-endo, which is also expressed in activated T
cells. Thus, a second marker, such as CD45, was needed to
distinguish these cells.17 The same approach was adopted for
CD31, which recognizes PECAM-1 present in endothelial cells,
platelets, monocytes, granulocytes and B cells, which were
also excluded by CD45. Anti-VEGFR2 and CD144 are endothe-
lial cell markers, as they bind to the VEGF and VE-Cadherin
receptors, respectively. In addition, by differentiating between
mature and precursor endothelial cells, CD133 helped the
identiﬁcation of CECs as a stem cell marker. CD34 expression
on endothelial cells represents a problem for CEC evaluation as
its expression is also found in hematopoietic stem cells,17 and
this marker can be shown in mature and immature endothe-
lial cells.32
Another study performed with deep vein thrombosis (DVT)
patients and controls using the same three panels as this study
suggested that the use of only one panel may not be sufﬁcient
to accurately analyze CECs. In this study, a higher sensitivity
for CEC detection was observed for one of the panels (Panel 1)
rather than the other two (unpublished data). Regarding the
results obtained with DVT patients, we hypothesized that the
use of two or more  panels could increase the accuracy of the
analysis under certain clinical conditions. We  believe that the
expression of some epitopes may be altered by some diseases.
Conclusions
Any of these combinations of markers can be used to success-
fully determine CECs in healthy individuals with the use of two
or more  panels to conﬁrm the results. More  accurate studies
performed with these cells should increase our understand-
ing regarding their physiology and involvement in reparative
processes favoring their potential application in the clinical
practice.
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